Chugai Pharmaceutical Co., Ltd.
4519
Clasificación en acciones
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Precio por acción
$41.60
Capitalización bursátil
$68.46B
Cambio (1 día)
0.94%
Cambio (1 año)
-7.40%
País
JP
Comercio Chugai Pharmaceutical Co., Ltd. (4519)
Categoría
Healthcare
Historial del precio de la acción de Chugai Pharmaceutical Co., Ltd. (4519)
Precio más alto de cierre: $38.86 el 2026-10-01
Precio más bajo de cierre: $51.75 el 2000-11-01
Precio más bajo de cierre: $51.75 el 2000-11-01
Historial del precio de la acción de Chugai Pharmaceutical Co., Ltd. desde 2000 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -7.35% |
| 2025 | 24.85% |
| 2024 | 17.22% |
| 2023 | 54.46% |
| 2022 | -26.90% |
| 2021 | -29.65% |
| 2020 | 549.58% |
| 2019 | -29.61% |
| 2018 | 118.94% |
| 2017 | 21.69% |
| 2016 | -66.07% |
| 2015 | 245.37% |
| 2014 | 26.29% |
| 2013 | -97.98% |
| 2012 | 161.03% |
| 2011 | -12.65% |
| 2010 | -8.22% |
| 2009 | 13.93% |
| 2008 | 6.97% |
| 2007 | -20.27% |
| 2006 | -7.51% |
| 2005 | 47.49% |
| 2004 | 2.63% |
| 2003 | 84.70% |
| 2002 | -39.16% |
| 2001 | -23.39% |
| 2000 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $1.27K | 56.64% |
US
|
|
| $257.61 | 33.52% |
US
|
|
| $284.48 | 24.40% |
US
|
|
| $149.84 | 71.03% |
US
|
|
| $482.98 | 31.03% |
CH
|
